Focus on new generation research and developmentcancerCellular immunotherapy company Yushibo said on the 18th that it will recruit until 2022nobel prizeAward winner Caroline Bertozzi serves as chief scientific advisor. Caroline Bertozzi’s research into click chemistry is the scientific basis for Yushibo’s core technology. His expertise will assist Yushibo in the continued development of innovative approaches to disease treatment.
The appointment was celebrated on September 13 at the IEXPO Annual Symposium in the San Francisco Bay Area, attended by members of leading pharmaceutical companies, professional investors and academic experts.
Caroline Bertozzi won the Nobel Prize in Chemistry in 2022 for her work based on a new type of “click chemistry,” also known as bioorthogonal chemistry. This revolutionary method uses bioorthogonal reactions to apply click chemistry to living cells, which can be performed in vivo, integrate seamlessly with cell functions, and do not interfere with the normal functions of cells.
Their research advances more scientific applications to study cell biology, monitor biological responses, and more effectively improve disease specificity in cancer. Caroline Bertozzi is Professor of Chemistry at Stanford University and Howard HughesMedicineA fellow at the center, she is a member of the National Academy of Sciences, the National Academy of Medicine, and the National Academy of Inventors, and serves as a key leader in advancing innovative approaches to treating a variety of diseases, including cancer .
Xiao Shijia, CEO of Yushibo, said that it is an honor to invite Caroline Bertozzi to participate in advancing the clinical trial project. His early research and development experience in immune cell therapy has led to the development of antibody cell connection (ACC) technology. Platform, starting with Caroline. Bertozzi’s laboratory, a company dedicated to advancing a pipeline of novel cell-based medicines to treat solid tumors and blood cancers, is pleased to have his support.
Caroline Bertozzi also said that Yushibo is changing the current approach to cell therapy development by introducing antibody cell connection technology. The Yushibo team will clearly have a major impact on the field of treating diseases. He is eager to work with the team and work together. Promote important advances with the ultimate goal of improving existing treatment options for patients.
As Chief Scientific Advisor, Caroline Bertozzi will lead the company’s Scientific Advisory Board, which includes immunology experts and leaders in innovative treatment strategies to guide the company’s scientific progress and provide insights based on its relevant experience.
Yushibo Biotechnology Co., Ltd. was founded in 2017 by Taiwanese PhD Yang Yumin and PhD Xiao Shijia. The company is based in Taipei and the San Francisco Bay Area of the United States. This is a company dedicated to developing a new generation of cancer cell immunotherapy. It uses the core technology platform “antibody-cell” connect technology (ACC), which develops a series of new immune cell therapy drugs and is one of the few allogeneic cell therapy technology developments. Companies in Taiwan.
The “antibody-cell connection (ACC)” technology invented by Shijia Xiao inherits the cutting-edge research results of Dr. Caroline Bertozzi in bioorthogonal chemistry, and further applies click chemistry to living organisms. Yushibo’s technology platform and intellectual property rights are derived from the laboratory results of Professor Bertozzi and Professor Xiao Shijia at the University of California, Berkeley.
San Francisco(tagstotranslate)cancer
